Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

N

National Institute of Neurology and Neurosurgery, Mexico

Status and phase

Unknown
Phase 4

Conditions

Depressive Disorder, Treatment-Resistant

Treatments

Drug: Ketamine

Study type

Interventional

Funder types

Other

Identifiers

NCT02610712
63/13

Details and patient eligibility

About

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission and inflammatory serum markers.

Full description

The purpose of this study is to determine the efficacy of the use of intravenous low-dose ketamine (0.5 mg/kg) in the treatment of treatment-resistant depression (TRD), as well as the changes in Glutamate neurotransmission measured by Magnetic Resonance Imaging Spectroscopy and inflammatory serum markers (IL-6, TNF-alpha).

Enrollment

20 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Treatment-Resistant Depression (Failure to respond to two or more trials of antidepressant monotherapy or failure to respond to four or more trials of different antidepressant therapies)
  • Acceptance of participation via the informed consent

Exclusion criteria

  • Psychiatric comorbidity (except anxiety related disorders)
  • Substance abuse or dependence in the previous 3 months
  • Evidence of structural abnormalities in brain imaging
  • Pregnancy
  • Previous hypersensitivity to ketamine
  • Heart failure or insufficiency
  • Familial or personal history of psychosis
  • Glaucoma
  • Major neurological disease
  • Uncontrolled systemic arterial hypertension
  • MRI contraindications
  • Non-acceptance of participation via informed consent

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

TRD patients
Experimental group
Description:
Treatment-Resistant (TRD) patients to receive intravenous ketamine at 0.5 mg/kg dose.
Treatment:
Drug: Ketamine

Trial contacts and locations

1

Loading...

Central trial contact

Rodrigo Pérez-Esparza, MD; Jesús Ramírez-Bermúdez, MD, MSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems